{"retracted":false,"update":{"timestamp":1475280000000,"doi":"10.1016/j.ygyno.2016.07.097","type":"erratum"},"doi":"10.1016/j.ygyno.2016.05.015","journal":"Gynecologic Oncology","publisher":"Elsevier BV","title":"Corrigendum to “Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center” [Gynecol. Oncol. 142 (2016) 13–18]"}
